Shire PLC (LON:SHP)‘s stock had its “buy” rating reissued by investment analysts at Deutsche Bank AG in a note issued to investors on Monday. They presently have a GBX 6,200 ($77.46) price objective on the biopharmaceutical company’s stock. Deutsche Bank AG’s price target indicates a potential upside of 27.77% from the company’s previous close.

Several other research analysts have also weighed in on SHP. Royal Bank Of Canada reiterated an “outperform” rating on shares of Shire PLC in a report on Friday, July 22nd. Shore Capital reiterated a “buy” rating on shares of Shire PLC in a report on Friday, July 22nd. BNP Paribas reiterated an “outperform” rating and set a GBX 5,700 ($71.21) target price on shares of Shire PLC in a report on Tuesday, July 26th. Liberum Capital reiterated a “buy” rating and set a GBX 5,500 ($68.72) target price on shares of Shire PLC in a report on Friday, July 29th. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating and set a GBX 6,300 ($78.71) target price (up from GBX 5,600 ($69.97)) on shares of Shire PLC in a report on Monday, August 1st. One research analyst has rated the stock with a sell rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of GBX 5,992.27 ($74.87).

Analyst Recommendations for Shire PLC (LON:SHP)

Shire PLC (LON:SHP) opened at 4852.50 on Monday. The stock’s 50 day moving average price is GBX 4,957.26 and its 200-day moving average price is GBX 4,707.98. Shire PLC has a one year low of GBX 2,707.19 and a one year high of GBX 5,377.00. The firm’s market cap is GBX 43.68 billion.

In other news, insider Dominic Blakemore bought 133 shares of the firm’s stock in a transaction dated Friday, September 30th. The shares were bought at an average price of GBX 5,010 ($62.59) per share, with a total value of £6,663.30 ($8,324.96).

About Shire PLC

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.